Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events

IMPORTANCE: In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive prote...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Cardiol
Hlavní autoři: Sehested, Thomas S. G., Bjerre, Jenny, Ku, Seul, Chang, Andrew, Jahansouz, Alison, Owens, Douglas K., Hlatky, Mark A., Goldhaber-Fiebert, Jeremy D.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2019
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439626/
https://ncbi.nlm.nih.gov/pubmed/30649147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2018.4566
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky